AZ’s STORM CHASER Falls Short On Ambitious COVID Symptom Goal

But Data Point To Success

 
• By Andrew McConaghie

AstraZeneca had wanted to outperform Regeneron and Lilly in post-exposure prevention, but will now hope for more durable protection from its long-acting antibody.

AZ building
AstraZeneca has agreed a $691m advance purchase deal on its long-acting antibody therapy with the US government, contingent on regulatory approval.

More from Business

More from Scrip